Ophthotech Corporation

Ophthotech Corporation

Ophthotech Corporation was founded in the early 2000s as a biotech spinout, with its headquarters in Princeton, New Jersey. The firm concentrated on treating retinal disorders such as wet age-related macular degeneration and geographic atrophy, leveraging anti-PDGF and complement pathway mechanisms. The company's strategy centered on developing Fovista (pegpleranib), a platelet-derived growth factor inhibitor intended for use in combination with anti-VEGF therapies like Lucentis or Eylea. In 2016, Ophthotech reported Phase 3 results showing Fovista failed to meet primary endpoints of visual acuity improvement, leading to a 90% stock drop. Subsequent pipeline assets included complement factor D inhibitors for geographic atrophy and anti-amyloid beta candidates. The firm raised approximately $300M in equity financing across private and public rounds, including a 2012 IPO on NASDAQ. By early 2020, Ophthotech had fewer than 50 employees and no approved products. In September 2020, Iconic Therapeutics acquired Ophthotech in an all-stock transaction valued at about $50M, and the combined entity rebranded as Iveric Bio. The firm held no adjacent vehicles or philanthropic structures as a standalone entity. A structural differentiator was Ophthotech's targeted focus on ophthalmic therapies via a single-drug pipeline—a high-risk, high-reward strategy common among development-stage biotechs but unusual for family-office profiles. The firm operated without a diversified portfolio or co-investment model, making its acquisition a natural exit for concentrated research capital.